SEC Form 4 · accession 0000899243-18-030797
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L Tubridy
Officer — SVP, Chief Development Officer
Period of report
Dec 12, 2018
Accepted (ET)
Dec 13, 2018 · 8:18 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2018 | F | 11,928 | $8.94 | D | 30,229 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 639 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018.
Remarks
Exhibit 24- Power of Attorney